Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
GlaxoSmithKline
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07609706CT.gov A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | — | Not Yet Recruiting | — | — | — |
NCT07614360CT.gov Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07285239CT.gov Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07601100CT.gov Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07428369CT.gov A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) | — | Withdrawn | — | — | — |
NCT07637526CT.gov Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07341867CT.gov Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | — | Not Yet Recruiting | — | — | — |
NCT07227311CT.gov A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) | — | Recruiting | — | — | — |
NCT07391657CT.gov A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | — | Recruiting | — | — | — |
NCT07222761CT.gov A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Recruiting | — | — | — |
Show 269 more trialsShow fewer
NCT07297329CT.gov A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | — | Recruiting | — | — | — |
NCT07018050CT.gov Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | — | Recruiting | — | — | — |
NCT07045909CT.gov Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) | — | Recruiting | — | — | — |
NCT05272826CT.gov Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients | — | Recruiting | — | — | — |
NCT06413498CT.gov A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06577025CT.gov A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06169215CT.gov Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06353022CT.gov Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06505369CT.gov Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT06158841CT.gov Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06464991CT.gov A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) | — | Recruiting | — | — | — |
NCT06152575CT.gov MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | — | Recruiting | — | — | — |
NCT06208150CT.gov A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | — | Recruiting | — | — | — |
NCT05567601CT.gov Doxil/Caelyx BE Study | — | Completed | — | — | — |
NCT06140966CT.gov Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05257083CT.gov A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05849610CT.gov Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03759093CT.gov CURATE.AI Optimized Modulation for Multiple Myeloma | — | Unknown | — | — | — |
NCT05804032CT.gov Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT05572515CT.gov A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05665140CT.gov Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT05556616CT.gov A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma | — | Terminated | — | — | — |
NCT05432414CT.gov PVd Versus Vd in NDMM Patients With RI | — | Unknown | — | — | — |
NCT05695508CT.gov GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | — | Recruiting | — | — | — |
NCT05623020CT.gov A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | — | Recruiting | — | — | — |
NCT05514990CT.gov Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | — | Active Not Recruiting | — | — | — |
NCT05558319CT.gov NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | — | Not Yet Recruiting | — | — | — |
NCT05519085CT.gov A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Recruiting | — | — | — |
NCT05137054CT.gov A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | — | Recruiting | — | — | — |
NCT05392946CT.gov Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | — | Active Not Recruiting | — | — | — |
NCT05422027CT.gov Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05900882CT.gov SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease | — | Recruiting | — | — | — |
NCT04975997CT.gov Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT04912427CT.gov Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease | — | Terminated | — | — | — |
NCT05147493CT.gov A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | — | Unknown | — | — | — |
NCT05123131CT.gov Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06956170CT.gov All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04892446CT.gov Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT04240054CT.gov Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency | — | Recruiting | — | — | — |
NCT05083169CT.gov A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04956302CT.gov Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT04923893CT.gov A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | — | Active Not Recruiting | — | — | — |
NCT06868654CT.gov China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06868667CT.gov Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04751877CT.gov Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | — | Active Not Recruiting | — | — | — |
NCT04877275CT.gov ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | — | Unknown | — | — | — |
NCT04802356CT.gov Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT04722146CT.gov A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04570631CT.gov Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT04484623CT.gov Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04414475CT.gov A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | — | Recruiting | — | — | — |
NCT04392648CT.gov A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Withdrawn | — | — | — |
NCT04181827CT.gov A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04246047CT.gov Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04352205CT.gov Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04268498CT.gov A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04091126CT.gov Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04133636CT.gov A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04052880CT.gov Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | — | Active Not Recruiting | — | — | — |
NCT03989414CT.gov A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | — | Active Not Recruiting | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03984097CT.gov A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) | — | Completed | — | — | — |
NCT03942224CT.gov Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03729804CT.gov Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | — | Active Not Recruiting | — | — | — |
NCT03829020CT.gov Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03651128CT.gov Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT03908138CT.gov RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | — | Unknown | — | — | — |
NCT03828292CT.gov An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments | — | Completed | — | — | — |
NCT03701321CT.gov Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03763162CT.gov Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03607643CT.gov A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | — | Unknown | — | — | — |
NCT03678883CT.gov 9-ING-41 in Patients With Advanced Cancers | — | Active Not Recruiting | — | — | — |
NCT03742297CT.gov Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | — | Active Not Recruiting | — | — | — |
NCT03617731CT.gov Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) | — | Active Not Recruiting | — | — | — |
NCT03544281CT.gov To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Completed | — | — | — |
NCT03589222CT.gov SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03412565CT.gov A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | — | Completed | — | — | — |
NCT03481556CT.gov Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM | — | Terminated | — | — | — |
NCT03314181CT.gov A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03416374CT.gov A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy | — | Completed | — | — | — |
NCT03319667CT.gov A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | — | Active Not Recruiting | — | — | — |
NCT03168100CT.gov 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03004287CT.gov 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | — | Active Not Recruiting | — | — | — |
NCT03110562CT.gov Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT03117361CT.gov Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide | — | Terminated | — | — | — |
NCT03000634CT.gov 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | — | Withdrawn | — | — | — |
NCT02928029CT.gov Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | — | Terminated | — | — | — |
NCT02773030CT.gov A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02605356CT.gov Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT02902965CT.gov Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02719613CT.gov Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | — | Completed | — | — | — |
NCT02755597CT.gov A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | — | Completed | — | — | — |
NCT02718833CT.gov A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02703779CT.gov Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT02343042CT.gov Selinexor and Backbone Treatments of Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT02577783CT.gov PDD vs PAD to Treat Initially Diagnosed MM | — | Unknown | — | — | — |
NCT02513186CT.gov Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation | — | Completed | — | — | — |
NCT02356159CT.gov Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | — | Completed | — | — | — |
NCT02514382CT.gov Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02440464CT.gov Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | — | Completed | — | — | — |
NCT02497378CT.gov A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02495922CT.gov A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma | — | Completed | — | — | — |
NCT02375555CT.gov Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | — | Completed | — | — | — |
NCT02555839CT.gov Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice | — | Completed | — | — | — |
NCT02362035CT.gov ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | — | Completed | — | — | — |
NCT02220608CT.gov Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT02211014CT.gov An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT02254551CT.gov Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT02328014CT.gov Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | — | Completed | — | — | — |
NCT02290431CT.gov Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02188537CT.gov Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma | — | Completed | — | — | — |
NCT02424851CT.gov Optimising Renal Outcome in Myeloma Renal Failure | — | Completed | — | — | — |
NCT02186834CT.gov Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02206425CT.gov Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | — | Completed | — | — | — |
NCT02188368CT.gov Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | — | Terminated | — | — | — |
NCT02128230CT.gov UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | — | Terminated | — | — | — |
NCT02100657CT.gov Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01863550CT.gov Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02027220CT.gov Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma | — | Unknown | — | — | — |
NCT01965353CT.gov A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01818752CT.gov Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01849783CT.gov Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01827137CT.gov WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | — | Completed | — | — | — |
NCT01440582CT.gov Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | — | Completed | — | — | — |
NCT01680796CT.gov Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01734928CT.gov Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01711528CT.gov Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT01852799CT.gov A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01794507CT.gov A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | — | Completed | — | — | — |
NCT01668719CT.gov S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma | — | Completed | — | — | — |
NCT01602224CT.gov A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT01568866CT.gov Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients | — | Completed | — | — | — |
NCT01537861CT.gov Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01246063CT.gov Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01548573CT.gov Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | — | Terminated | — | — | — |
NCT01531998CT.gov Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT01492881CT.gov Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01497093CT.gov Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01541332CT.gov Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT01534143CT.gov High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | — | Terminated | — | — | — |
NCT01539083CT.gov Velcade (Bortezomib) Consolidation After Transplant | — | Completed | — | — | — |
NCT01485835CT.gov A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01337752CT.gov Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency | — | Completed | — | — | — |
NCT01329289CT.gov SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01428492CT.gov Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT01478048CT.gov Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01359657CT.gov Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01212952CT.gov Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01394354CT.gov Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT01055301CT.gov S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01470131CT.gov A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01163357CT.gov Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | — | Completed | — | — | — |
NCT01183949CT.gov Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | — | Completed | — | — | — |
NCT01215344CT.gov First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | — | Completed | — | — | — |
NCT00568880CT.gov Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01078441CT.gov Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | — | Terminated | — | — | — |
NCT01328236CT.gov Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia | — | Unknown | — | — | — |
NCT01164709CT.gov Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer | — | Completed | — | — | — |
NCT02559154CT.gov Modified Bortezomib-based Combination Therapy for Multiple Myeloma | — | Unknown | — | — | — |
NCT01083602CT.gov Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01009840CT.gov IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | — | Completed | — | — | — |
NCT01063907CT.gov A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01034553CT.gov Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01038388CT.gov A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT02858999CT.gov Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 | — | Completed | — | — | — |
NCT01023308CT.gov Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT01002248CT.gov Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | — | Terminated | — | — | — |
NCT01160484CT.gov Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00903968CT.gov Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00925821CT.gov Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00920556CT.gov A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT00837200CT.gov Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | — | Terminated | — | — | — |
NCT00871013CT.gov Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT00858234CT.gov Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) | — | Completed | — | — | — |
NCT00839956CT.gov Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant | — | Completed | — | — | — |
NCT00872521CT.gov A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00773838CT.gov Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | — | Completed | — | — | — |
NCT00773747CT.gov Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | — | Completed | — | — | — |
NCT00849251CT.gov Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT00744354CT.gov Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00869232CT.gov UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | — | Active Not Recruiting | — | — | — |
NCT00750815CT.gov Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT00765102CT.gov Trial of Romidepsin and Bortezomib for Multiple Myeloma | — | Terminated | — | — | — |
NCT00720785CT.gov Natural Killer Cells and Bortezomib to Treat Cancer | — | Completed | — | — | — |
NCT00697346CT.gov Study of MLN8237 in Participants With Advanced Hematological Malignancies | — | Completed | — | — | — |
NCT00742404CT.gov Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT00706953CT.gov A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | — | Withdrawn | — | — | — |
NCT00708292CT.gov A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | — | Completed | — | — | — |
NCT00719901CT.gov Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00734877CT.gov UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | — | Active Not Recruiting | — | — | — |
NCT00664898CT.gov A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00724568CT.gov Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00670631CT.gov Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment | — | Completed | — | — | — |
NCT00560352CT.gov Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | — | Terminated | — | — | — |
NCT00546780CT.gov A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse | — | Completed | — | — | — |
NCT00792142CT.gov Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma | — | Completed | — | — | — |
NCT00555906CT.gov An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. | — | Completed | — | — | — |
NCT00617591CT.gov Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT00536575CT.gov Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00520130CT.gov Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | — | Completed | — | — | — |
NCT00602511CT.gov Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma | — | Completed | — | — | — |
NCT00608907CT.gov An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | — | Completed | — | — | — |
NCT00514371CT.gov A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00507416CT.gov Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone | — | Completed | — | — | — |
NCT00504101CT.gov Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | — | Withdrawn | — | — | — |
NCT00483262CT.gov Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00577512CT.gov 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE | — | Completed | — | — | — |
NCT00652041CT.gov Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT00401843CT.gov A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00431990CT.gov A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | — | Unknown | — | — | — |
NCT00458705CT.gov Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00572169CT.gov UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | — | Active Not Recruiting | — | — | — |
NCT00438841CT.gov Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma | — | Unknown | — | — | — |
NCT00401011CT.gov Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients | — | Completed | — | — | — |
NCT01370434CT.gov Two Cycles of PAD Combination by AHCT in MM | — | Completed | — | — | — |
NCT00574080CT.gov UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | — | Terminated | — | — | — |
NCT00523848CT.gov Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma | — | Completed | — | — | — |
NCT00315757CT.gov Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00461747CT.gov GEM05 for Patients With Multiple Myeloma Under 65 Years | — | Completed | — | — | — |
NCT00401804CT.gov Bortezomib-Dexamethasone-Doxorubicin-Study | — | Completed | — | — | — |
NCT00334932CT.gov Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma | — | Unknown | — | — | — |
NCT00310024CT.gov Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00561743CT.gov A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00319865CT.gov PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT00111813CT.gov Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | — | Completed | — | — | — |
NCT00243035CT.gov Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | — | Terminated | — | — | — |
NCT00124579CT.gov S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00148317CT.gov Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma | — | Completed | — | — | — |
NCT00116961CT.gov Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma | — | Completed | — | — | — |
NCT00258245CT.gov Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | — | Completed | — | — | — |
NCT00097981CT.gov A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00358020CT.gov Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00985907CT.gov Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00516191CT.gov A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT00287872CT.gov Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma | — | Completed | — | — | — |
NCT00054158CT.gov Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma | — | Completed | — | — | — |
NCT00153933CT.gov Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00201695CT.gov Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma | — | Completed | — | — | — |
NCT00135187CT.gov Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma | — | Completed | — | — | — |
NCT00088855CT.gov Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma | — | Completed | — | — | — |
NCT00082784CT.gov Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | — | Completed | — | — | — |
NCT00581919CT.gov Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma | — | Completed | — | — | — |
NCT00080925CT.gov T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies | — | Completed | — | — | — |
NCT00093028CT.gov Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II | — | Completed | — | — | — |
NCT00074490CT.gov Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | — | Terminated | — | — | — |
NCT00215943CT.gov Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | — | Terminated | — | — | — |
NCT01070862CT.gov Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies. | — | Completed | — | — | — |
NCT00222105CT.gov A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life | — | Completed | — | — | — |
NCT00580372CT.gov UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00036790CT.gov Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00577096CT.gov Effects of Exercise in Combination With Epoetin Alfa | — | Completed | — | — | — |
NCT00083915CT.gov DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | — | Completed | — | — | — |
NCT00237627CT.gov Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00028886CT.gov Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma | — | Unknown | — | — | — |
NCT00006184CT.gov Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | — | Completed | — | — | — |
NCT00083538CT.gov Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | — | Completed | — | — | — |
NCT00008242CT.gov Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma | — | Completed | — | — | — |
NCT00560053CT.gov Pethema Multiple Myeloma 2000 | — | Completed | — | — | — |
NCT00003493CT.gov Combination Chemotherapy in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00083551CT.gov UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | — | Completed | — | — | — |
NCT00002878CT.gov Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00006232CT.gov Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma | — | Completed | — | — | — |
NCT00002657CT.gov SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant | — | Completed | — | — | — |
NCT00002599CT.gov Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma | — | Unknown | — | — | — |
NCT00002548CT.gov SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma | — | Completed | — | — | — |
NCT00995059CT.gov Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Withdrawn | — | — | — |
NCT02666209CT.gov Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | — | No Longer Available | — | — | — |
NCT02658396CT.gov GO-203-2C + Bortezomib For Relapsed Or Refractory MM | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | GlaxoSmithKline | Approved | BB · 70 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →